Zobrazeno 1 - 10
of 1 298
pro vyhledávání: '"Josep, Tabernero"'
Autor:
Neil H. Segal, Ignacio Melero, Victor Moreno, Neeltje Steeghs, Aurelien Marabelle, Kristoffer Rohrberg, Maria E. Rodriguez-Ruiz, Joseph P. Eder, Cathy Eng, Gulam A. Manji, Daniel Waterkamp, Barbara Leutgeb, Said Bouseida, Nick Flinn, Meghna Das Thakur, Markus C. Elze, Hartmut Koeppen, Candice Jamois, Meret Martin-Facklam, Christopher H. Lieu, Emiliano Calvo, Luis Paz-Ares, Josep Tabernero, Guillem Argilés
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours in two open-label
Externí odkaz:
https://doaj.org/article/c7ab25df143a4df7a0b711f295ef7d2c
Autor:
Takayuki Yoshino, Josep Tabernero, Jin Yao, Amit Mahipal, Eric Chen, Heinz-Josef Lenz, Aparna Parikh, Timothy Larson, Dustin Deming, David R Spigel, Allen L Cohn, Mark Kochenderfer, Elena Elez, Spencer H Shao, Regan Holdridge, Antonio Ucar, Dana Cullen, Edwina Baskin-Bey, Tong Kang, Amy B Hammell
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in combination with st
Externí odkaz:
https://doaj.org/article/4248b125094a414a9758f28ab9189376
Autor:
Núria Mulet Margalef, Carmen Castillo, Miguel Mosteiro, Xavier Pérez, Susana Aguilar, Fiorella Ruíz‐Pace, Marta Gil, Carmen Cuadra, José Carlos Ruffinelli, Mercedes Martínez, Ferran Losa, Gema Soler, Àlex Teulé, Roser Castany, Rosa Gallego, Andrea Ruíz, Elena Garralda, Elena Élez, Ana Vivancos, Josep Tabernero, Ramon Salazar, Rodrigo Dienstmann, Cristina Santos Vivas
Publikováno v:
Molecular Oncology, Vol 17, Iss 9, Pp 1908-1916 (2023)
Efficiency of expanded genomic profiling (EGP) programmes in terms of final inclusion of patients in genomically matched therapies is still unknown. Fit patients with advanced and refractory colorectal cancer (CRC) were selected for an EGP programme.
Externí odkaz:
https://doaj.org/article/2839a020268549238eafbd6acf6b31ac
Autor:
Clara Salva de Torres, Iosune Baraibar, Nadia Saoudi González, Javier Ros, Francesc Salva, Marta Rodríguez-Castells, Adriana Alcaraz, Ariadna García, Josep Tabernero, Elena Élez
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 13, p 6967 (2024)
The treatment of unresectable metastatic colorectal cancer has evolved over the last two decades, as knowledge of cancer biology has broadened and new targets have emerged. ‘The Hallmarks of Cancer’ illustrate the crucial capabilities acquired by
Externí odkaz:
https://doaj.org/article/2b7dd858f5dc458aa423ba2f5c92806e
Autor:
Maria-Josep Carreras, Elena Tomás-Guillén, Anna Farriols, Berta Renedo-Miró, Carolina Valdivia, Jana Vidal, Cristina Saura, Joan Carles, Enriqueta Felip, Maria-Queralt Gorgas, Josep Tabernero, Josep Monterde
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 7984-8004 (2023)
Background: Cancer is one of the leading causes of morbidity and mortality in the world. Its growing incidence and prevalence, as well as the advances in diagnostic and treatment tools, motivate an open debate about the economic burden it may place o
Externí odkaz:
https://doaj.org/article/693da0fcbdaa4f0cad78276db01bf51c
Autor:
Kai Zimmer, Florian Kocher, Gerold Untergasser, Brigitte Kircher, Arno Amann, Yasmine Baca, Joanne Xiu, W. Micheal Korn, Martin D. Berger, Heinz-Josef Lenz, Alberto Puccini, Elisa Fontana, Anthony F. Shields, John L. Marshall, Michael Hall, Wafik S. El-Deiry, David Hsiehchen, Teresa Macarulla, Josep Tabernero, Renate Pichler, Moh’d Khushman, Upender Manne, Emil Lou, Dominik Wolf, Viktorija Sokolova, Simon Schnaiter, Alain G. Zeimet, Pat Gulhati, Gerlig Widmann, Andreas Seeber
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-9 (2023)
Abstract Polybromo-1 (PBRM1) loss of function mutations are present in a fraction of biliary tract cancers (BTCs). PBRM1, a subunit of the PBAF chromatin-remodeling complex, is involved in DNA damage repair. Herein, we aimed to decipher the molecular
Externí odkaz:
https://doaj.org/article/5241117531c4407f8106f8137c687dda
Autor:
Elisabeth G. E. deVries, Josef Rüschoff, Martijn Lolkema, Josep Tabernero, Luca Gianni, Emile Voest, Derk Jan A. deGroot, Daniel Castellano, Gilles Erb, Julia Naab, Margarita Donica, Regula Deurloo, Michiel S. van derHeijden, Giuseppe Viale
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12071-12083 (2023)
Abstract The antibody‐drug conjugate trastuzumab emtansine (T‐DM1) is approved for human epidermal growth factor receptor 2 (HER2/ERBB2)–positive breast cancer. We aimed to study tumor HER2 expression and its effects on T‐DM1 responses in pat
Externí odkaz:
https://doaj.org/article/0f7c9c9a50584cb282318c9ac1965648
Autor:
Maria-Josep Carreras, Berta Renedo-Miró, Carolina Valdivia, Elena Tomás-Guillén, Anna Farriols, Laura Mañós, Jana Vidal, María Alcalde, Isabel De la Paz, Inés Jiménez-Lozano, Maria-Eugenia Palacio-Lacambra, Nuria Sabaté, Enriqueta Felip, Elena Garralda, Margarita Garau, Maria-Queralt Gorgas, Josep Monterde, Josep Tabernero
Publikováno v:
Cancers, Vol 16, Iss 8, p 1529 (2024)
The objective of this single-center retrospective study was to describe the clinical characteristics of adult patients with solid tumors enrolled in cancer clinical trials over a 10-year period (2010–2019) and to assess drug cost avoidance (DCA) as
Externí odkaz:
https://doaj.org/article/c111996a2e304338aabaf30c78bc7c8f
Autor:
Javier Ros, Caterina Vaghi, Iosune Baraibar, Nadia Saoudi González, Marta Rodríguez-Castells, Ariadna García, Adriana Alcaraz, Francesc Salva, Josep Tabernero, Elena Elez
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 6, p 3304 (2024)
Kirsten rat sarcoma virus oncogene homolog (KRAS) is the most frequently mutated oncogene in human cancer. In colorectal cancer (CRC), KRAS mutations are present in more than 50% of cases, and the KRAS glycine-to-cysteine mutation at codon 12 (KRAS G
Externí odkaz:
https://doaj.org/article/359f4672f3584830911456d8cf8acf9d
Autor:
David Elvira, Ferran Torres, Roser Vives, Gemma Puig, Mercè Obach, Daniel Gay, Daniel Varón, Thais de Pando, Josep Tabernero, Caridad Pontes
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
IntroductionEven using well-established technology assessment processes, the basis of the decisions on drug price and reimbursement are sometimes perceived as poorly informed and sometimes may be seen as disconnected from value. The literature remain
Externí odkaz:
https://doaj.org/article/c0c6fd588b57467b97b8226c53b556ce